Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment
Creators
- 1. Department of Radiation Oncology, Marilia Medical School, Maria Cecilia Alves, 192, Marilia, São Paulo (Brazil)
- 2. Department of Radiation Oncology, Marilia Medical School, Marília, São Paulo (Brazil)
- 3. Marilia Medical School, Marília (FAMEMA), São Paulo (Brazil)
Description
To compare the acute toxicities in radical treatment of prostate cancer between conventional schedule (C-ARM) with 78 Gy/39 fractions and hypofractionation conformal treatment (H-ARM) with 69 Gy/23 fractions. This prospective double arm study consisted of 217 patients with prostate cancer, 112 in H-ARM and 105 in C-ARM arm. C-ARM received conventional six- field conformal radiotherapy with 78 Gy in 39 fractions while H-ARM received hypofractionation with 69 Gy in 23 fractions. Weekly assessment of acute reactions was done during treatment and with one, and 3 months using RTOG scale. Univariated analysis was performed to evaluate differences between the incidences of acute reaction in the treatment arms. Variables with p value less than 0.1 were included in the multivariated logistic regression. There was no difference between H-ARM versus C-ARM for severity and incidence in genitourinary (GU) and gastrointestinal (GI) acute toxicity. During the treatment comparing H-ARM with C-ARM no differences was observed for GI toxicity (grade 0–3; H-ARM = 45.5%, 34%, 18.7% and 1.8% versus C-ARM = 47.6%, 35.2%, 17.2% and 0). For acute GU toxicity no difference was detected between H-ARM (grade 0–3; 22.3%, 54.5%, 18.7% and 4.5%) and C-ARM (grade 0–3; 25.8%, 53.3%, 17.1% and 3.8%). At the 3- months follow-up, persistent Grade > =2 acute GU and GI toxicity were 2.5% and 1.8% in H-ARM versus 5.7% and 3% in C-ARM (p > 0.05). In univariated and multivariated analyses, there was not any dosimetric predictor for GI and GU toxicity. Our data demonstrate that hypofractionated radiotherapy achieving high biological effective dose using conformal radiotherapy is feasible for prostate cancer, being well tolerated with minimal severe acute toxicity
Availability note (English)
Available from http://dx.doi.org/10.1186/1748-717X-8-94; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642008Additional details
Identifiers
Publishing Information
- Journal Title
- Radiation Oncology (Online)
- Journal Volume
- 8
- Journal Page Range
- p. 94
- ISSN
- 1748-717X
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47062118
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ARMS; FRACTIONATED IRRADIATION; GY RANGE 10-100; NEOPLASMS; PROSTATE; RADIOTHERAPY; TOXICITY
- Descriptors DEC
- ABSORBED DOSE RANGE; BODY; DISEASES; GLANDS; GY RANGE; IRRADIATION; LIMBS; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2013 Viani et al.
- Notes
- PMCID: PMC3642008; PUBLISHER-ID: 1748-717X-8-94; PMID: 23601254; OAI: oai:pubmedcentral.nih.gov:3642008; licensee BioMed Central Ltd.